Real world analysis of second-line osimertinib use for NSCLC in North West London

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, of the Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses his group's real world analysis of the use of second-line osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC) across North West London, which was presented at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland. Dr Newsom-Davis highlights the notable results in terms of EGFR mutation testing and the rates of treatment with osimertinib, and draws attention to how these data can impact economic evaluation; namely, NICE evaluation of osimertinib in the first-line setting.